Derivative exercise or conversion — not an open-market buy.
Loading…
Planned for Sep 4, 2026 · Notice filed Sep 4, 2026
A board member of Idexx Laboratories told the SEC they plan to sell $1.17M of Idexx Laboratories shares around Sep 4, 2026. The shares came from their pay, which is the usual reason to sell.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
None found in footnotes
Only flagged when a footnote says so; never inferred
Derivative exercise or conversion — not an open-market buy.
12K → 9,568 shares held−19% of their stake
A board member of Idexx Laboratories sold $1.17M of Idexx Laboratories shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.